Acura Pharmaceuticals Inc
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminoph… Read more
Market Cap & Net Worth: Acura Pharmaceuticals Inc (ACUR)
Acura Pharmaceuticals Inc (OTCQB:ACUR) has a market capitalization of $1.31 Million ($1.31 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #44528 globally and #14104 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Acura Pharmaceuticals Inc's stock price $0.02 by its total outstanding shares 66001783 (66.00 Million).
Acura Pharmaceuticals Inc Market Cap History: 2015 to 2025
Acura Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows change from $165.00 Million to $1.31 Million (-40.51% CAGR).
Acura Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Acura Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.11x
Acura Pharmaceuticals Inc's market cap is 21.11 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $165.00 Million | $8.59 Million | -$4.99 Million | 19.22x | N/A |
| 2016 | $50.59 Million | $4.46 Million | -$7.39 Million | 11.33x | N/A |
| 2017 | $26.66 Million | $2.97 Million | -$5.68 Million | 8.99x | N/A |
| 2018 | $7.58 Million | $410.00K | -$3.84 Million | 18.50x | N/A |
| 2019 | $15.18 Million | $2.66 Million | -$3.77 Million | 5.71x | N/A |
| 2020 | $13.86 Million | $3.57 Million | -$1.21 Million | 3.88x | N/A |
| 2021 | $33.00 Million | $1.56 Million | -$879.00K | 21.11x | N/A |
Competitor Companies of ACUR by Market Capitalization
Companies near Acura Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Acura Pharmaceuticals Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Acura Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Acura Pharmaceuticals Inc's market cap moved from $165.00 Million to $ 1.31 Million, with a yearly change of -40.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.31 Million | +760.87% |
| 2024 | $151.80K | +2200.00% |
| 2023 | $6.60K | -99.80% |
| 2022 | $3.30 Million | -90.00% |
| 2021 | $33.00 Million | +138.10% |
| 2020 | $13.86 Million | -8.70% |
| 2019 | $15.18 Million | +100.17% |
| 2018 | $7.58 Million | -71.55% |
| 2017 | $26.66 Million | -47.31% |
| 2016 | $50.59 Million | -69.34% |
| 2015 | $165.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Acura Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.31 Million USD |
| MoneyControl | $1.31 Million USD |
| MarketWatch | $1.31 Million USD |
| marketcap.company | $1.31 Million USD |
| Reuters | $1.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.